Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budigalimab (Primary) ; Rovalpituzumab tesirine (Primary) ; Venetoclax (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AbbVie

    • Most Recent Events

    • 15 Jul 2022 Results by obtaining plasma samples from NCT03000257 and other studies evaluating the association between baseline plasma ARG levels and the clinical benefit of ICIs, published in the Annals of Oncology
    • 13 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2022 Results of biomarker analyses published in the Journal of Immunotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top